Breaking Finance News

ValuEngine upgraded Spectranetics Corp (NASDAQ:SPNC) to Hold in a report released today.

Just yesterday Spectranetics Corp (NASDAQ:SPNC) traded 0.00% even at $29.05. Spectranetics Corp’s 50-day moving average is $37.28 and its 200-day moving average is $30.10. The last closing price is down 27.74% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same time period. 1,728,937 shares of SPNC traded hands, up from an average trading volume of 1,458,700

ValuEngine has upgraded Spectranetics Corp (NASDAQ:SPNC) to Hold in a report released on Friday June 02, 2017.

Recent Performance Chart

Spectranetics Corp (NASDAQ:SPNC)

Spectranetics Corp has with a one year low of $19.80 and a one year high of $38.55 and has a total market value of $0.

A total of 11 equity analysts have released a ratings update on SPNC. Four equity analysts rating the company a strong buy, four equity analysts rating the company a buy, two equity analysts rating the company a hold, one equity analyst rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $20.05.

Brief Synopsis About Spectranetics Corp (NASDAQ:SPNC)

The Spectranetics Corporation develops, manufactures, markets and distributes single-use medical devices used in minimally invasive procedures within the cardiovascular system. The Company's products are used to cross, prepare and treat arterial blockages in the heart and legs and to manage pacemaker and defibrillator cardiac leads. Its geographic segments are U.S. Medical and International Medical. Its product offerings in U.S. Medical segment include medical devices used in minimally invasive procedures within the cardiovascular system, including fiber-optic devices and non-fiber-optic products (disposables), an excimer laser system (equipment) and the service of the excimer laser system (service). Its products are used in multiple vascular procedures, including peripheral atherectomy, crossing arterial blockages, coronary atherectomy and thrombectomy. Its International Medical segment is primarily engaged in distribution activities.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *